Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 8, 2014, Pages 1667-1677

  Lainé, Anne Laure ^a,b   Clavreul, Anne ^b   Rousseau, Audrey ^b   Tétaud, Clément ^b   Vessieres, Anne ^c   Garcion, Emmanuel ^a,b   Jaouen, Gerard ^c   Aubert, Léo ^d   Guilbert, Matthieu ^d   Benoit, Jean Pierre ^a,b   Toillon, Robert Alain ^d   Passirani, Catherine ^a,b  

^a UNIVERSITÉ D'ANGERS   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c CNRS   (France)

^d INSERM   (France)

Author keywords

Ansa FcdiOH; Cell cycle; EPR effect; Nanomedicine

Indexed keywords

BRAIN; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CELLS; CHEMOTHERAPY; CYTOLOGY; DAMAGE DETECTION; DISEASES; MEDICAL NANOTECHNOLOGY; NANOCAPSULES;

ANSA-FCDIOH; ANTICANCER EFFECTS; CANCER CHEMOTHERAPY; CELL CYCLE; EPR EFFECT; INTRAVENOUS INJECTIONS; LIPID NANOCAPSULES; PROLIFERATIVE CELLS;

TUMORS;

ANTINEOPLASTIC AGENT; FERROCENE DERIVATIVE; LIPID NANOCAPSULE; NANOCAPSULE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; DRUG CARRIER; FERROUS ION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL SURVIVAL; CELL VIABILITY; CIRCULATION TIME; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GLIOMA; HYDRODYNAMICS; IC50; IMMUNE RESPONSE; IMMUNITY; IN VITRO STUDY; LIVER HISTOLOGY; LIVER INJURY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; NONHUMAN; OSMOLARITY; PLASMA CLEARANCE; RAT; T LYMPHOCYTE; ZETA POTENTIAL; ANIMAL; CELL CYCLE; CHEMISTRY; DRUG EFFECTS; FISCHER 344 RAT; NANOMEDICINE; TUMOR CELL LINE;

ANIMALS; CELL CYCLE; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; FERROUS COMPOUNDS; GLIOMA; NANOCAPSULES; NANOMEDICINE; RATS; RATS, INBRED F344; REACTIVE OXYGEN SPECIES;

EID: 84908567803     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.05.002     Document Type: Article

References (38)

1. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J.B., Janzer R.C., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
2. Vessières A. Metal carbonyl tracers and the ferrocifen family: Two facets of bioorganometallic chemistry. J Organomet Chem 2013, 734:3-16.
3. Görmen M., Pigeon P., Top S., Hillard E.A., Huché M., Hartinger C.G., et al. Synthesis, cytotoxicity, and COMPARE analysis of ferrocene and [3]ferrocenophane tetrasubstituted olefin derivatives against human cancer cells. ChemMedChem 2010, 5:2039-2050.
4. Lainé A.-L., Adriaenssens E., Vessières A., Jaouen G., Corbet C., Desruelles E., et al. The in vivo performance of ferrocenyl tamoxifen lipid nanocapsules in xenografted triple negative breast cancer. Biomaterials 2013, 34:6949-6956.
5. Laine A.-L., Huynh N.T., Clavreul A., Balzeau J., Béjaud J., Vessieres A., et al. Brain tumour targeting strategies via coated ferrociphenol lipid nanocapsules. Eur J Pharm Biopharm 2012, 81:690-693.
6. Huynh N.T., Passirani C., Allard-Vannier E., Lemaire L., Roux J., Garcion E., et al. Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma. Int J Pharm 2012, 423:55-62.
7. Roger M., Clavreul A., Huynh N.T., Passirani C., Schiller P., Vessières A., et al. Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int J Pharm 2012, 423:63-68.
8. Plazuk D., Vessières A., Hillard E.A., Buriez O., Labbé E., Pigeon P., et al. A [3]ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines. J Med Chem 2009, 52:4964-4967.
9. Büyüktimkin B., Wang Q., Kiptoo P., Stewart J.M., Berkland C., Siahaan T.J. Vaccine-like controlled-release delivery of an immunomodulating peptide to treat experimental autoimmune encephalomyelitis. Mol Pharm 2012, 9:979-985.
10. Gu Z., Aimetti A.A., Wang Q., Dang T.T., Zhang Y., Veiseh O., et al. Injectable nano-network for glucose-mediated insulin delivery. ACS Nano 2013, 7:4194-4201.
11. Jia F., Liu X., Li L., Mallapragada S., Narasimhan B., Wang Q. Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J Control Release 2013, 172:1020-1034.
12. Prabhakar U., Maeda H., Jain R.K., Sevick-Muraca E.M., Zamboni W., Farokhzad O.C., et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 2013, 73:2412-2417.
13. Jokerst J.V., Lobovkina T., Zare R.N., Gambhir S.S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 2011, 6:715-728.
14. Huynh N.T., Roger E., Lautram N., Benoît J.-P., Passirani C. The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. Nanomedicine (Lond) 2010, 5:1415-1433.
15. Huynh N.T., Passirani C., Saulnier P., Benoit J.P. Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 2009, 379:201-209.
16. Perrier T., Saulnier P., Fouchet F., Lautram N., Benoît J.-P. Post-insertion into lipid nanocapsules (LNCs): From experimental aspects to mechanisms. Int J Pharm 2010, 396:204-209.
17. Uster P.S., Allen T.M., Daniel B.E., Mendez C.J., Newman M.S., Zhu G.Z. Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett 1996, 386:243-246.
18. Hoarau D., Delmas P., David S., Roux E., Leroux J.-C. Novel long-circulating lipid nanocapsules. Pharm Res 2004, 21:1783-1789.
19. Purkayastha S., Berliner A., Fernando S.S., Ranasinghe B., Ray I., Tariq H., et al. Curcumin blocks brain tumor formation. Brain Res 2009, 10.1016/j.brainres.2009.01.066.
20. Zanotto-Filho A., Coradini K., Braganhol E., Schröder R., de Oliveira C.M., Simões-Pires A., et al. Curcumin-loaded lipid-core nanocapsules as a strategy to improve pharmacological efficacy of curcumin in glioma treatment. Eur J Pharm Biopharm 2012, 10.1016/j.ejpb.2012.10.019.
21. Lainé A-L, Gravier J, Henry M, Sancey L, Bejaud J, Pancani, E, et al. Conventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoring. J Control Release http://dx.doi.org/10.1016/j.jconrel.2014.05.042 [in press].
22. Barras A., Mezzetti A., Richard A., Lazzaroni S., Roux S., Melnyk P., et al. Formulation and characterization of polyphenol-loaded lipid nanocapsules. Int J Pharm 2009, 379:270-277.
23. Oteiza P.I., Erlejman A.G., Verstraeten S.V., Keen C.L., Fraga C.G. Flavonoid-membrane interactions: a protective role of flavonoids at the membrane surface?. Clin Dev Immunol 2005, 12:19-25.
24. Paillard A., Hindré F., Vignes-Colombeix C., Benoit J.-P., Garcion E. The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials 2010, 31:7542-7554.
25. Illán-Cabeza N.A., García-García A.R., Martínez-Martos J.M., Ramírez-Expósito M.J., Peña-Ruiz T., Moreno-Carretero M.N. A potential antitumor agent, (6-amino-1-methyl-5-nitrosouracilato-N3)-triphenylphosphine-gold(I): Structural studies and in vivo biological effects against experimental glioma. Eur J Med Chem 2013, 64:260-272.
26. Vidimar V., Meng X., Klajner M., Licona C., Fetzer L., Harlepp S., et al. Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. Biochem Pharmacol 2012, 84:1428-1436.
27. Sharma V., Joseph C., Ghosh S., Agarwal A., Mishra M.K., Sen E. Kaempferol induces apoptosis in glioblastoma cells through oxidative stress. Mol Cancer Ther 2007, 6:2544-2553.
28. Thayyullathil F., Chathoth S., Hago A., Patel M., Galadari S. Rapid reactive oxygen species (ROS) generation induced by curcumin leads to caspase-dependent and -independent apoptosis in L929 cells. Free Radic Biol Med 2008, 45:1403-1412.
29. Kim K., Kim J.H., Park H., Kim Y.-S., Park K., Nam H., et al. Tumor-homing multifunctional nanoparticles for cancer theragnosis: simultaneous diagnosis, drug delivery, and therapeutic monitoring. J Control Release 2010, 146:219-227.
30. Ishida T., Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 2008, 354:56-62.
31. Knop K., Hoogenboom R., Fischer D., Schubert U.S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl 2010, 49:6288-6308.
32. Tinnemans M.M.F.J., Lenders M.-H.J.H., ten Velde G.P.M., Blijham G.H., Ramaekers F.C.S., Schutte B. S-phase arrest of nutrient deprived lung cancer cells. Cytometry 1995, 19:326-333.
33. Borel F., Lacroix F.B., Margolis R.L. Prolonged arrest of mammalian cells at the G1/S boundary results in permanent S phase stasis. J Cell Sci 2002, 115:2829-2838.
34. Barth R.F., Kaur B. Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol 2009, 94:299-312.
35. Floyd J., Mirza I., Sachs B., Perry M.C. Hepatotoxicity of chemotherapy. Semin Oncol 2006, 33:50-67.
36. Lu Y., Cederbaum A.I. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol Sci 2006, 89:515-523.
37. Lainé A.-L., Passirani C. Novel metal-based anticancer drugs: a new challenge in drug delivery. Curr Opin Pharmacol 2012, 12:420-426.
38. Li M., Deng H., Peng H., Wang Q. Functional nanoparticles in targeting glioma diagnosis and therapies. J Nanosci Nanotechnol 2014, 14:415-432.